[Level of hormones of pituitary-gonadal axis, penile blood flow and sexual function in men with arterial hypertension during monotherapy with bisoprolol and nebivolol].

Measurement of levels of hormones of the pituitary-gonadal system, dopplerography of penile arteries and questioning after Vasiltchenko were carried out in 30 men (age 35-55 years) with I-II degree arterial hypertension who received monotherapy with bisoprolol and nebivolol for 2 months. Treatment with both superselective beta-adrenoblockers was associated with significant lowering of systolic and diastolic blood pressure and heart rate. Antihypertensive effect of bisoprolol was significantly more pronounced than that of nebivolol. Bisoprolol and nebivolol significantly increased concentration of testosterone (by 82 and 85%, respectively) and prolactin (by 77 and 83%, respectively), lowered levels of estradiol and follicle-stimulating hormone, improved vascular blood flow in penile arteries, and did not worsen sexual function.

[Effect of long-term treatment with prazosin and its combination with nadolol on the levels of blood hormones of the hypophyseal- gonadal system in patients with hypertension]. / Vliianie dlitel'noi terapii prazozinomi ego kombinatsiei s nadololom na soderzhanie v krovi gormonov gipofizarno-gonadnoi sistemy u bol'nykh gipertonicheskoi bolezn'iu.

The levels of pituitary and gonadal hormones were measured by radioimmunoassay during a long-term (12-month) therapy with prazosin and its combination in 23 patients aged 30-59 years who suffered from Stage II hypertensive disease. Prazosin monotherapy resulted in a significant decrease in prolactin levels, followed by inhibited elaboration of luteinizing, follicle-stimulating, and testicular hormones in the first 6 months of therapy without changing estradiol levels. The hypoprolactinemic effect of prazosin was significantly enhanced with an increase in therapy duration and more profound in patients who had high baseline prolactin levels and in younger patients. Prazosin in combination with nadolol was found to level off the hyperprolactinemic effect of the latter without potentiating the reduction in the levels of follicle-stimulating, luteinizing, and testicular hormones which was observed during therapy with each drug alone.

[Prognosis of the probability of development of ischemic heart disease with regard to family anamnesis in a Baku male population of 20-54 years of age]. / Prognoz veroiatnosti razvitiia ishemicheskoi bolezni serdtsa s uchetom dannykh semeinogo anamneza u muzhchin bakinskoi populiatsii v vozraste 20-54 let.

The analysis of the results obtained from a genetic population survey among an unorganized Baku male population aged 20-54 years provided quantitative assessments of a set of informative signs to reveal the factors predisposing to coronary heart disease. Predictive indicators of empirical and theoretical risk of the disease were constructed on the basis of the signs selected.

[State of the hypophyseal-gonadal system in patients with hypertension during long-term treatment with nadolol and anaprilin]. / Sostoianie gipofizarno-gonadnoi sistemy u bol'nykh gipertonicheskoi bolezn'iu pri dlitel'nom lechenii nadololom i anaprilinom.

The changes in hormone levels of the hypophyseal-gonadal system were studied during 6-month monotherapy with nadolol, 40-160 mg/day, or anaprilin, 80-240 mg/day, in 40 males with Stage II hypertensive disease. Serum levels of prolactin, luteinizing, follicle-stimulating, and testicular hormones, and estradiol were measured by radioimmunoassay at the end of control placebo, 2-week, 2- and 6-month therapy. The negative changes revealed in the hypophyseal-gonadal system, as manifested by elevated prolactin and estradiol levels, diminished testicular hormone concentration, indicate that the levels of these hormones should be monitored in a long-term antihypertensive therapy with beta-adrenoblockers.

[The effect of long-term treatment with nadolol on serum levels of thyroid hormones and thyrotropin in patients with hypertension]. / Vliianie dlitel'nogo lecheniia nadololom na uroven' gormonov shchitovidnoi zhelezy i tireotropnogo gormona v syvorotke krovi u bol'nykh gipertonicheskoi bolezn'iu.

In 20 males with Stage II hypertensive disease, effects of 2-week-, 2-, and 6-month monotherapy with nadolol given in doses 40 to 160 mg daily were examined on the levels of thyroidal hormones (T3 and T4) and thyroid-stimulating hormone. At the all stages of the therapy, the mean values of the examined parameters were significantly unchanged. Nadolol was found to cause a decrease in T3 concentrations at its high baseline values (r = -0.57; p less than 0.05) and in doses greater than 40 mg daily. With reduced T3 levels, there were elevated T4 levels in most cases. An inverse relationship was established between the altered serum T3 levels and the thyroid-stimulating hormone concentration.